Inhalation Sciences Sweden AB (publ) releases Q3 Report 2021
(
Summary of the interim report
The clinical trial of PreciseInhale is ongoing and follows the schedule. ISAB expects to be able to present final results and data for publishing data within the coming months.
This quarter, the company has signed several large orders with both new and returning customers. The company had an order backlog of
CEO statement
During the third quarter, there have been easing of the restrictions for both travel and meetings, and for us this has meant that we have been able to carry out service and training visits to customers, mainly in
At the same time, we have continued our dialogues with existing and new potential customers and seen results in the form of a number of new orders. This is a positive result of discussions and negotiations that in some cases have been going on for over a year. In connection with increased sales and marketing activities, our outstanding quotes have also increased by approximately 50% compared with the same period last year.
The activities around our clinical study continue according to plan, both operationally and budgetarily. As we have previously communicated, we expect to be able to present the final results and basis for a clinical publication within the coming months. This is one of the biggest milestones in the company’s history and we are very much looking forward to completing the ongoing work on the study.
Regarding our IR operations, we have initiated a new collaboration with Redeye. In addition to company analyzes, Redeye will assist ISAB with an expanded investment network and information dissemination in the form of company and CEO presentations.
The coming fourth quarter will be crucial for what 2021 looks like as a whole. I, together with my team at ISAB, am dedicated to ending the year well and continuing the work of building the company further and taking the right next step in our continued commercialization phase.
Huddinge
Manoush Masarrat
vd
For more information about Inhalation Science, please contact:
Manoush Masarrat, VD
Email: [email protected]
Mobile: +46 (0) 73 628 9153
About
The information was provided by the company’s CEO for publication on
https://mb.cision.com/Main/15842/3459220/1500476.pdf
https://mb.cision.com/Public/15842/3459220/8ee33ca3fb14ee8a.pdf
(c) 2021 Cision. All rights reserved., Source